Halozyme Therapeutics (HALO) Rating Lowered to Hold at Zacks Investment Research

Zacks Investment Research cut shares of Halozyme Therapeutics (NASDAQ:HALO) from a buy rating to a hold rating in a research report report published on Monday.

According to Zacks, “Halozyme Therapeutics, Inc. is a therapeutically driven, development stage biopharmaceutical company dedicated to developing and commercializing recombinant human enzymes for the infertility, ophthalmology, and oncology communities. The company’s broad product development portfolio, including expected near- and long-term product offerings, is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company’s initial products are being developed to offer safer and purer alternatives toexisting slaughterhouse derived extracts that carry risks of pathogen contamination, immunogenicity, and toxicity. The commercialization of Halozyme’s highly versatile enzyme technology within proven markets will enable the company to positively impact the quality of medicine. “

Other research analysts have also issued research reports about the company. Deutsche Bank increased their price target on Halozyme Therapeutics to $20.00 and gave the stock a buy rating in a research note on Friday, September 15th. Canaccord Genuity increased their price target on Halozyme Therapeutics from $17.00 to $19.00 and gave the stock a buy rating in a research note on Wednesday, November 8th. BidaskClub raised Halozyme Therapeutics from a hold rating to a buy rating in a research note on Tuesday, December 12th. Barclays lowered Halozyme Therapeutics from an overweight rating to a hold rating and increased their price target for the stock from $16.00 to $19.00 in a research note on Wednesday, November 22nd. Finally, BMO Capital Markets increased their price target on Halozyme Therapeutics from $14.00 to $15.00 and gave the stock a market perform rating in a research note on Friday, September 15th. One analyst has rated the stock with a sell rating, five have given a hold rating and four have given a buy rating to the stock. The stock has a consensus rating of Hold and a consensus price target of $18.50.

Shares of Halozyme Therapeutics (HALO) opened at $20.71 on Monday. The company has a market capitalization of $2,880.00, a price-to-earnings ratio of -30.46 and a beta of 2.08. The company has a current ratio of 3.46, a quick ratio of 3.37 and a debt-to-equity ratio of 2.01. Halozyme Therapeutics has a fifty-two week low of $9.68 and a fifty-two week high of $21.10.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Tuesday, November 7th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.04). The company had revenue of $63.73 million for the quarter, compared to analyst estimates of $58.95 million. Halozyme Therapeutics had a negative net margin of 53.17% and a negative return on equity of 892.57%. Halozyme Therapeutics’s quarterly revenue was up 100.1% compared to the same quarter last year. During the same quarter last year, the company posted ($0.23) EPS. equities research analysts forecast that Halozyme Therapeutics will post 0.2 earnings per share for the current year.

Institutional investors have recently modified their holdings of the business. Teacher Retirement System of Texas purchased a new position in shares of Halozyme Therapeutics during the 2nd quarter worth $129,000. Arrowstreet Capital Limited Partnership purchased a new position in shares of Halozyme Therapeutics in the 2nd quarter worth $131,000. Prudential Financial Inc. raised its position in shares of Halozyme Therapeutics by 8.7% in the 2nd quarter. Prudential Financial Inc. now owns 11,726 shares of the biopharmaceutical company’s stock worth $150,000 after buying an additional 940 shares during the period. 361 Capital LLC purchased a new position in shares of Halozyme Therapeutics in the 3rd quarter worth $207,000. Finally, Trexquant Investment LP purchased a new position in shares of Halozyme Therapeutics in the 3rd quarter worth $224,000. 84.45% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This story was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another site, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this story can be read at https://www.dispatchtribunal.com/2017/12/29/halozyme-therapeutics-halo-rating-lowered-to-hold-at-zacks-investment-research.html.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.

Get a free copy of the Zacks research report on Halozyme Therapeutics (HALO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply